APRETUDE now covered for HIV prevention in Canada

ViiV Healthcare has announced that its HIV prevention medication, APRETUDE, is now covered under Canada's Non-Insured Health Benefits (NIHB) Program. This program provides essential health services to First Nations and Inuit people. APRETUDE is used for pre-exposure prophylaxis (PrEP) to help prevent HIV-1 infection in at-risk individuals. About 10% of people living with HIV in Canada are Indigenous, even though they only make up 5% of the population. The addition of APRETUDE to the NIHB Program aims to improve access to HIV prevention for these communities, struggling with higher rates of the virus due to various social and economic challenges. APRETUDE is notable because it is the first long-acting injectable option available in Canada. Research shows it is over 99% effective in preventing HIV when used properly. It has been found to work better than daily oral medications in clinical studies. Officials from ViiV Healthcare praised the NIHB Program for prioritizing HIV prevention in Indigenous communities. They hope to expand access to this medication for all Canadians who could benefit from PrEP. Health leaders stress that improving access to prevention is important, but investment in Indigenous-led health initiatives is also needed for lasting impact. HIV affects the immune system and can lead to AIDS if untreated. In 2023, there were 2,434 new diagnoses of HIV in Canada, highlighting the need for effective prevention options like APRETUDE.